Hello, and welcome, everyone, joining today's Merivai Life Sciences Q1 2026 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. To register to ask a question at any time, please press star 1 on your telephone keypad. Please note this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Deb Hart, Head of Investor Relations. Please go ahead.

Good afternoon, everyone. Thanks for joining us for our first quarter 2026 earnings call. The press release and slides accompanying today's call are posted on our website and available at investors.maravai.com. As you can see from the agenda on slide two, our CEO, Vern Brust, will provide a business update, and our CFO, Raj Asapoda, will review our financial results. Dr. Chen Feng Zhao, our chief scientific officer, will join us for the Q&A session. Management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today's call. It's possible that actual results could differ from expectations. We refer you to slide 3 for details on forward-looking statements and our use of non-GAAP financial measures. The press release provides reconciliations to the most directly comparable gap measures, and we also post reconciling schedules to our investor website. Please also refer to Maravai's SEC filings for additional information on the risks and uncertainties that may impact our operating results, performance, and financial condition. Now I'll turn the call over to Bernd.

Good afternoon, and thank you for joining us. We are very pleased with our first quarter performance, which represents a strong start to 2026 and builds on the momentum we exited with last year. The quarter results reflect solid execution across the business and reinforce our confidence in the trajectory we outlined on our call in February. Turning to slide five, we delivered total Q1 revenue of $65.8 million. dollars. That's 41% year-over-year growth and 10% year-over-year growth in our base business when you exclude COVID-related clean cap revenue. This performance was driven by improved Trilink demand, steady contribution from Cygnus, and continued progress against our strategic priorities. Trilink revenue grew 65% year-over-year with a base business growth of 15%, supported by strong demand in both GMP and Discovery consumables. At Cygnus, revenue grew a little more than 1% year-over-year. We saw solid underlying momentum with high single-digit growth in North America and low single-digit growth in EMEA, reinforcing our confidence in the positioning of the business. This was partially offset by lower contributions from China due to distributor ordering timing. From a profitability standpoint, we delivered adjusted gross margin of 65.3% and adjusted EBITDA of $20.3 million. These results reflect the benefit of higher revenue, favorable product and customer mix, and the cost disciplines we have implemented across the organization. We also generated $4.2 million of positive free cash flow in the quarter, which is the first time the company has been cash flow positive since Q3 of 2024. We see this as another clear indication that the structural improvements we have made are taking hold. Given our strong start to the year and improved visibility into the balance of 2026, we are increasing the range for our full year revenue expectations and substantially raising our EBITDA guidance Raj will walk through that in more detail shortly now let's turn to slide 6 for an update on our performance against our three strategic pillars commercial execution operational excellence and of course innovation starting with commercial execution we are seeing strong momentum across the business our increased focus on customer engagement is translating into better forecasting improve visibility and stronger order conversion we are securing more annual and multi-quarter purchase orders which is improving the stability and predictability of our revenue base this is a meaningful shift from where we were a year ago and reflects the effectiveness of the changes we have made in our commercial go-to-market approach that said our business has a disproportionate number of large orders that can result in quarter over quarter performance variation large orders tend to align with customer program progression and as a result revenue can vary between periods what gives us confidence is not the timing of any single order but the strength and continued expansion of the underlying opportunity funnel within tri-link our portfolio now spans enabling technologies such as CleanCap and Matel, along with custom and catalog mRNA, enzymes, oligonucleotides, including guide RNAs, and a broad range of nucleotide chemistries, including NTPs. This breadth allows us to participate more deeply across the mRNA and gene therapy workflows. We also recently launched all-in-one IVT kits, which simplify the production of capped RNA and provide early-stage researchers with easier access to our platform at TriLink our model continues to work as intended we establish relationships early in discovery and better technologies and customer workflows and then grow with those programs as they advance into GMP mentions of trialing technologies and scientific publications remain strong underscoring their role in customer workflows which we view as an important leading indicator of future demand The key highlight in the quarter is the continued adoption of Mottail. We now have more than 70 customers using this technology, across both large pharmaceutical companies and emerging biotechs. We are seeing growth in new customers, repeat orders, and increasing use across multiple applications. We also see continued strength in our GMP funnel, with GMP customers expected to grow 22% in 2026, representing nine existing REO customers transitioning to GMP customers two of which we have already converted this year many of these programs are progressing into later clinical stages which supports the durability of the demand as a long-term GMP supplier at Cygnus we saw growth from our newer DNA quantification and extraction kits as well as from our mock fee product offering these product lines extend us beyond our traditional HCP franchise into adjacent applications while still early we are encouraged by the traction we are seeing as customers look for high quality analytical tools across their development and manufacturing workflows and finally at sickness our kits continue to play a critical role in the market with a hundred percent attach rate supporting the safety testing of all 29 of the 29 FDA or EMA approved CAR-T cell and gene therapies. Now turning to operational excellence, this remains a core focus and a key driver of our improved financial performance. The restructuring actions implemented last year continue to deliver results and we now expect to achieve more than $65 million in annual EBITDA savings. These savings span labor, facilities, and controllable spend and are creating a more efficient and scalable cost structure this is clearly reflected in our margins we are benefiting from both cost discipline and a favorable product mix particularly as higher margin GMP consumables represent a larger portion of our revenue at the same time our operating model is now positioned to absorb incremental volume without significant increases in fixed costs supporting continued margin expansion as we grow revenue we are also making progress on our digital and operational initiatives. Our e-commerce channel continues to expand with more customers facing orders directly through our platform, improving speed and efficiency. In Q1, our website delivered record revenue, reflecting both improved customer engagement and the scalability of our digital platform. Finally, turning to R&D, our focus remains on translating innovation into revenue and strengthening our competitive position across our customers workflows at TriLink we are making strong progress on our enzymes portfolio our GMP facility has not been completed and we expect to launch GMP quality enzymes this quarter early customer engagement has been encouraging and we see this as an important extension of our capabilities with Mattel we are building on a strong discovery adoption and expect to launch GMP-grade Motel later this year, we are already seeing customer demand for GMP material to support clinical programs. This is a clear example of how our innovation pipeline feeds future revenue growth. More broadly, our portfolio continues to diversify across custom mRNA kits and catalog mRNA, complementing our existing clean cap and oligo product lines. This strengthens our position and reduces reliance on any single product or customer. At Cygnus, in addition to host cell protein assays, which remained a gold standard for clinical and commercial drug product lot release, we now offer an expanded suite of HCP analytical services utilizing advanced mass spectrometry methods and state-of-the-art instruments. These innovative analytical capabilities deliver critical insights to customers throughout drug development and into commercialization, helping ensure their products remain safe and effective. We continue to invest in and expand our IP portfolio across our core platforms, including CleanCap, ModTail and Cygnus assays. During the first quarter, TriLink received two additional European patents, including one further strengthening protection around our CleanCap technology and methods for synthesizing RNA. In addition, Cygnus was granted a new U.S. patent related to its MVP mock viral particle technology, supporting our assay and analytical capabilities. In summary, the first quarter represents an incredible start to the year. We are executing well across all three pillars, driving commercial momentum, delivering operational discipline, and advancing innovation. The fundamentals of the business are strong, and we believe we are well positioned for continued growth, margin expansion, and cash generation in 2026 and beyond. I'll now ask Raj to provide details on our first quarter performance and our updated guidance. Raj?

Thank you, Bernd. Building on Bernd's comments, the first quarter reflects solid execution across both segments with improving base demand and strong margin flow-through. I'll focus on the key drivers behind the quarter including revenue composition, profitability and our updated outlook. Let me start with a closer look at revenue on slide eight. Our business remains well diversified across end markets. Base revenue by customer type was 32% biopharma, 31% life sciences and diagnostics, 4% academia, 7% CRO, CMO, CDMO and 26% distributors. By geography base revenue was 60% North America, 25% EMEA, 8% Asia Pacific, excluding China, and 7% in China. Turning to slide nine, our gap net loss before non-controlling interest was $6.4 million. This compares to a gap net loss before non-controlling interest of $52.9 million in the prior year period. Adjusted EBITDA, a non-GAAP measure, was $20.3 million for Q1, exceeding our expectations and improving by more than $30 million year-over-year. This was driven by stronger revenue, favorable mix toward high-margin GMP and discovery consumables, and high-margin contribution from COVID clean cap. Basic and diluted loss per share in Q1 was $0.02 compared to a loss of $0.21 per share in Q1 2025. Adjusted EPS was positive $0.01 compared to a loss of $0.08 per share last year. Moving to the balance sheet, cash flow, and other financial metrics on slide 10. We ended the quarter with $165.9 million in cash and $242.9 million in long-term debt following the voluntary $50 million debt repayment during the quarter. We generated $4.2 million of positive free cash flow, reflecting improved EBITDA and disciplined capital management. Depreciation and amortization was $11.4 million, net interest expense was $3.9 million, and stock-based compensation, a non-cash charge, was $6.7 million for the quarter. Turning to segment performance on slide 11, TriLink represented 72% of total revenue in the quarter. Excluding COVID clean cap, Trialink represented 64% of total revenue with base growth of 15%. Trialink was a primary driver of adjusted EBITDA improvement, benefiting from high margin product mix and improved operating leverage. The segment generated 17.3 million of adjusted EBITDA representing an improvement of more than 26 million year-over-year. Cygnus represented 28% of total revenue or 36 percent of base revenue and continue to deliver strong profitability Cygnus generated 13.6 million of adjusted EBITDA with margins of 73.8 percent corporate expenses impacting adjusted EBITDA were 10.5 million in the quarter these expenses include HR finance legal IT and public company costs Turning to our updated guidance on slide 12, our outlook reflects a strong first quarter and increased confidence in the base business trajectory. We are raising our revenue range to $205 million to $215 million, representing growth of 10% to 16% over 2025. We expect trialing to grow in the high teens, driven by continued strength in GMP consumables and a return to growth and discovery. We do not currently expect additional high-volume COVID clean cap revenue in 2026. However, we continue to view $10 million to $20 million of annual endemic demand as a reasonable baseline longer term. For Cygnus, we continue to expect low to mid-single-digit growth, and we view the Q1 softness in China as timing-related. We are substantially raising our full-year adjusted EBITDA guidance to $30 to $32 million, representing an improvement of $61 to $63 million year-over-year, primarily driven by performance in TriLink. This reflects the composition of the growth we're seeing. We continue to see strong demand in higher margin areas of the portfolio, particularly GMP consumables or higher margin discovery consumables and key Cygnus product lines. That mixed shift, combined with structural improvements we've made, is driving the outperformance in EBITDA. Additionally, we expect continued gross margin expansion of greater than 1,300 basis points, supported by restructuring actions, cost discipline, and favorable product mix. The remainder of our guidance framework we provided in February's call is unchanged. Importantly, we expect to generate positive free cash flow for the remainder of the year, representing a meaningful improvement from 2025. Overall, we are encouraged by the momentum in the business. Improved commercial execution, a more efficient cost structure, and favorable mix are driving meaningful financial progress, and we remain confident in our outlook for 2026. With that, I'll turn the call back over to the operator for Q&A.

Thank you. At this time, if you would like to ask a question, please press star 1 now on your telephone keypad. To leave the queue at any time, please press star 2. Once again, that is star 1 to ask a question. Please limit yourself to one question and one follow-up. And we'll pause for just a moment to allow everyone a chance to join the queue. Thank you. We'll take our first question from Matt Hewitt with Craig Hallam Capital Group. Please go ahead.

Your line is open. well congratulations on a very nice start to the year maybe first up in real high level i'm just curious what you're seeing um from your pharma and customers both and kind of segmented large versus small and your expectations for those two groups as the year progresses obviously the funding um has improved and there's been a lot of talk about that but But what are you seeing from a spending perspective for that, the smaller pharma and biotech group? Thanks for the comment, Greg. Or Matt, I'm sorry.

When we look at that group, it's kind of consistent across the board. You know, big pharma has been very healthy in specifically some larger discovery orders. But discovery or smaller biotech, smaller pharma has been pretty consistent as well. Across the board, I think the area where we still see the most significant softness is in this academic research world. That's not a huge part of our revenue any longer. But when it comes to pharma, biotech, it's pretty consistent, healthy.

That's great. And then maybe just speaking to China, obviously there's a little bit of an order timing issue there. But it sounds like that's going to pick up. But as a whole, when you look at the year, is China starting to come back, or what are you seeing?

When you look at our Cygnus business, we have one distributor who represents us there. They're a solid company. We are certainly continuing to explore other commercialization options there. Raj and Dr. Zalewich in China last week for both Cygnus and TriLink. So we look at China for this year probably still as a sort of mid-single digits growth engine, and I think we should be able to get there. The problem is a little bit, these are all larger orders, right? There's not really any run rate modeling behind that. But we feel good in general about where that is sitting. On the trialing front, we really haven't done much business in China. It was actually the main purpose for being in China last week. We had some great interactions with customers there. I think you're going to see some progression happening there over the next months to come. And so China as a whole, revenue-wise, not a super critical component of the business, but certainly something we're going to continue to work on enhancing.

That's great, and congratulations again on the start of the year.

Thank you very much.

Thank you. We'll now move on to Matt Stanton with Jeffries. Your line is open.

Hey, thanks. Maybe to go back to the demand question, just the base TriLink business mid-teens growth year-over-year, can you just unpack the demand a little bit more, what you saw in Discovery versus GMP? I think you said you expect GMP to grow over 20% for the year. Did you see that here in 1Q? And then the last quarter, you sounded pretty upbeat on kind of order trends, final activity. Would just kind of love to hear how that trended for the rest of 1Q and here into 2Q in terms of some of the future demand indicators. They're assumed pretty good just given the guidance raised, but we'd love to get any more anecdotal color just on some of the funnel and order activity as well for discovering Yeah.

Hey, Matt, thanks for the question. I think when you look at TriLink, like we said, that grew 15 percent. And while that Q1 kind of base growth was strong, as you can extrapolate for the balance of the year, like we said, there's some variability in larger GMP orders. We characterize that underlying growth in the second half in trialing to be in the low to mid single digits. And we do remain very positive on the longer term trajectory. And as we kind of look for more consistent growth, we have, you know, we talked about Mottail as a particular call out on the R&D side that is starting to kind of get a get good traction.

We've seen revenues from last year into this year. steadily climbing and then as that starts to turn into gmp level in the second half we should see some more positive growth as these programs get traction towards the end of the year and into next year right and then maybe just on mod tail just um it sounds like you know how is that tracking to expectations sounds like maybe better 70 customers new customers repeat orders um and then the scope to launch the gmp in the back half of the year just how meaningful is that and was that kind of accelerated as it relate as it relates to what you've seen so far and the activity levels on that product thank you yeah I think certainly no

motel is well performing above what our expectations are 70 customers is a pretty big number I think the the dollar amount is right in line with what we had expected for the whole year that it's still a fairly small portion of our total revenues of course it being a newly launched product but but the fact that we have some larger customers already asking for GMP quality product is pretty unique so early on after a launch. So, yeah, we're moving quickly on that based on somebody's earlier customer indications. I don't think the GMP consumables in Mottail will have a material impact in 2026. But certainly, if you start seeing demand there, it should set us up for a very nice 2027 for that product life.

Thank you.

We'll move next to Justin Bowers with Deutsche Bank. Your line is open. Please go ahead.

Good afternoon, everyone. Can you talk about the funnel and how that's shaping up and maybe any metrics around growth there and RFPs over the last few quarters or few months? And then also what you're seeing in terms of decisions and timelines there, any change in the velocity?

Let me maybe give a high-level comment, and I'll let Raj get maybe into some more details here. On the GMP front, the funnels continue to be good. I think we pointed out in our comments earlier that we have nine or so new discovery customers that are moving into clinical trials forecasted for this year. Two have already started. The remainders. we're expecting sometime in the remainder of this year to start you know that funnel is always fairly easy to to manage just because it has a fairly fairly long outlook and so we have a pretty good grasp on what's happening there and it's good growth for the remainder of this year on the larger discovery orders it's been great velocity and in fact has been faster than we had expected customers that we were expecting to buy later in the year but earlier in the year hopefully that's a good indication around them accelerating their their experiments their work and further further growth moving forward the challenge in that part of this is a little bit is it for us that the average sales cycle there is like two or two or three months and so with GMP we pretty much know in advance what's going to happen and there's large discovery segments we don't quite grasp yet what's going to happen in Q3 and Q4 just given again the sales cycle that comes with this the trajectory has been great you know we see no reason why that shouldn't continue that way certainly that's what we are seeing in the first four and a half months or now of this year but but all in all great great growth trajectory in both areas now I think you covered

it Barent I mean maybe on discovery again if you you know we segment those under 15K and greater than 15K orders, and as we've always said, under 15K, those orders are predominantly academic and early-stage research, and that segment, like we said, is still recovering, but it's consistent with our broader funding environment, and we did see modest growth in this segment in Q1, and then on greater than 15K discovery orders, those are kind of dominated by biopharma and biotech development programs, and those are seeing really healthy growth, like Barron said.

Thank you. Appreciate it.

Thank you. We'll move on now to Sabu Nambi with Guggenheim. Your line is open. Please go ahead.

Thank you for taking my question. How did the CDMO customer orders perform in the quarter, particularly for Cygnus?

Well, there's not. CDMO and Cygnus, I don't know if we've reported out. necessarily if you talk about CDMO and and some of our work we're doing with trialing that businesses is fairly steady we have we have a couple of great programs in there it's pretty smart small part of our business yet in this as we shared last year we restructured that organization a little bit just to control our costs but the programs that are there are doing well it's it's not a very large group so there's a lot of lumpiness again in there as well but I That's probably the only CDMO we break out. I don't know if we break CDMO out customer-wise for Cygnus. I don't think we have it in the past now.

Okay, that's helpful. And then when we think of Meravai, just zooming out, and we want to look at leading indicators, where should investors lean on? Should it be smaller biotech that are working on biologics? Should it be cell and gene therapy companies, or in general the whole bioprocessing end market?

I would go with your last suggestion. I think that the health across the board is starting to get much, much better. Like we said, we see that weakness still, and it's such a small part of our business, but it is in the academic, smaller research world.

Perfect. Thank you so much, Faith.

Thank you. We'll move on to Matthew Parisi with KeyBank Capital Markets. Your line is open. Please go ahead.

Hi, yes, this is Matthew Parisi on for Paul Knight. Congrats on the quarter and thanks for taking my question. As a percentage of revenue, APAC decreased pretty meaningfully in the quarter compared to the fourth quarter. I was wondering what drove that change and then is that a trend that you can expect for the rest of 2026?

I'll let Raj go through the details here, but my guess is that's largely through sickness. There's just not a lot of TriLink activity in that part of the world. So Raj, keep me honest there. TriLink, or I'm sorry, Cygnus, we talked about China. I think the other area was Korea, South Korea, where we saw some softness. I don't know whether we have great data behind it.

Really, it's not that meaningful. And again, going back to China, that current softness that we saw in the first quarter is really kind of distributor ordering pattern and it's not end customer driven we typically have good line of sight to what the end demand is and that is not impacted this is purely a timing issue so we don't see any significant shift for the balance of the year and that demand is not impacted so we feel pretty good about recovering the demand and the balance of the year thank you and i could just squeeze in one more.

I was just wondering about kind of how the engagement has been with the new MRNA builder.

Great. I mean, so early days, obviously, we saw the highest increase in online activities with the business in this quarter. Our total e-commerce revenues is still under 10% for the business, so it's still a long runway to go here, but good engagement. We've seen our first non-contact orders coming through, and highly optimistic that that will be a big driver, specifically as the academic world will bounce back at some point here that allows us to touch those customers without really increasing any kind of human interaction.

That's awesome. Thanks for taking my questions.

Thank you. And once again, if you would like to ask a question, please press star 1 on your keypad We'll now move on to Dan Arias with Stiefel. Your line is open.

This is Rohan. I'm for Dan. Thanks for the questions. Last year, you were pretty adamant that high volume clean cap visibility was near zero without binding purchase orders. And today, you've pinned the COVID-19 revenue at exactly $14.3 million. What specifically changed in your forecasting methodology or customer contracts that allows for this level of precision now?

I think that's a misunderstanding, guys. I think we shared last year that we expect COVID in 2026 to be between $10 and $20 million, and we expect that to be the same number kind of moving forward. We received orders in that this is the dollars that came in. And so we don't expect any other order for the rest of the year. But I don't think we ever said that we would not have any further COVID-related orders in 2026. We would have said that for 2025.

Okay, thanks for the clarity on that. And you raised the midpoint of adjusted EBITDA guidance by $12 million or so at the midpoint, right? While only raising revenue by $5 million. Well, aside from the restructuring savings, how much of this kind of change or delta is driven by a higher margin mix from ModTill or the GMP enzymes versus just kind of pure cost cutting?

Okay, so for EBITDA, you know, I think in Q1 we saw the EBITDA disproportionately tied to revenue. We are seeing great benefits, like we mentioned, from our commercial strategy, kind of focusing on high-value customers and programs. We've improved our pricing discipline and just managed that longer tail of lower-value transactions. So that, coupled with the favorable mix that we're seeing on GMP on the higher margin orders, is kind of improving the quality of revenue and the flow of EBITDA through that. on on top of that our operating expenses are tracking to plan and the cost reset that we did on the restructuring is fully embedded as we modeled and we're continuing to see savings there so those are some of the drivers on on the EBITDA performance do we do potentially put in a little risk on some of our lower margin service businesses not tied to commercialization just tied to project

and how well the success of those those projects be you know if you see some softness there won't impact our margins really in any material way so the product mix is truly a material impact of why we're seeing such great even out performance okay thank you for that and just if I could squeeze in one more question do you have GMP enzymes launching Q2 how much of the 2026 guidance raised is contingent on this launch and do you have any pre-orders in place from existing Flanders to customers thanks zero zero is is tied to that that revenue up call we had assumed this is going to happen we have orders in hand for GMP we're running our engineering runs at the moment I think we would start delivering those those GMP orders toward the end of this quarter into early next quarter.

Okay, thank you, guys. Thank you. We'll now move on to Matt LaRue with William Blair. Your line is open.

Good afternoon. Since the new team, Barron and Rob, you've been in place, obviously the focus has been on restructuring, right-sizing, kind of improving the operational health. And last quarter and this quarter, too, it has been as clearly has turned a corner and markets are improving as well. You know, you mentioned being over in China recently to talk about trialing, so some new business development opportunities, some benefits from the website in terms of record sales or new product launches upcoming. I guess as you think about shifting the organization sort of velocity or trajectory from one of restructuring and right-sizing to attacking new growth opportunities, what areas do you think, you know, are sort of the highest return or more senior-term things that you can do as, again, the market recovers and customers, you know, fingers crossed are looking to continue to spend more?

I think it's a great question. You know, I think maybe pointing out first and foremost, I'd like to really think the team that we put together here, and this was in July, August last year, really combined its focus both on the restructuring while at the same time focusing on how do we commercially grow this business again. And I think at the product front, you saw a great example from our R&D team and launching Mattel and the great response to that product. On the commercial front, you've seen the restructured organization bringing these products to the customers very effectively with more than 70 customers in place right now. And so, you know, I think the restructuring has happened really in parallel with this commercial effort. that I wouldn't say that that's what started first and now we are shifting that shit has happened for some time and I think that's why you're seeing the results I think as far as where do we see the biggest wins you're clearly you're seeing automation and AI coming into play with our smaller academic basic research orders we try to avoid having as we want to have a little interaction human interaction with with those types of orders and so the biggest windfalls the biggest the biggest gains I think clearly sit with big pharma small pharma biotech in this large discovery space where there's just a lot of uptick in activity and when we listen to our commercial teams a lot of interaction with customers there and then clearly you know the bet here is that you know a lot of that effort will lead into future GMP activities where these programs enter some stage of clinical trials and clearly that's the entire approach for for our business how do you get your discovery consumables in the GMP consumables and and and we're seeing a great great future for that as far as geographic is concerned you know obviously we're spending a majority of our time today between North America and EMEA I think you will start seeing an increased shift in focusing more on Asia I think there are opportunities there that we haven't captured I think it's a little bit early days I would say you You know, in timing of where we have chosen to spend our time, it has been to obviously right-size the business, but also focus commercially on the regions I just mentioned. So Asia, for sure, will see more effort. I think it's a little early to kind of talk about what that looks like.

Okay.

Thank you. And our final question will be from Matt Hewitt with Craig Hallam.

Your line is open. So, Hewitt, you may want to check your mute switch. Your line is open.

All right. with Matt not on the line why don't we turn it back to burn for some closing remarks thank you Deb I'll keep this short here as well thanks everybody for taking the time today to listen to our q1 results and some great questions like the results showed in q1 we feel great about where the business is heading when when we came in last year and the changes we were bringing forward that always leaves some concern for instability and we really haven't seen any of that kind of commented here also on a positive momentum in the market specifically in pharma and biotech which is really our bread and butter and so great Q1 we feel absolutely solid about the remainder of this year and we feel great about the market so Asia I think the question has come up a couple times I think there's opportunity for us rather than downside just because our exposure isn't that great there yet. But all in all, we feel great about the business. Appreciate your support and look forward to speaking again in about three months.

Thank you. This brings us to the end of today's meeting.

We appreciate your time and participation. You may now disconnect.